Circulating Tumor Cells and Colorectal Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lievre A, Bachet JB, Le Corre D, et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992–3995.
Ashworth T: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869.
Engell HC: Cancer cells in the circulating blood: a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation. Ugeskr Laeger 1955, 117:822–823.
Engell HC: Cancer cells in the blood: a five to nine year follow up study. Ann Surg 1959, 149:457–461.
Roberts S, Jonasson O, Long L, et al.: Clinical significance of cancer cells in the circulating blood: two to five-year survival. Ann Surg 1961, 154:362–370.
• Negin B, Cohen S: Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol 2010 Feb 9 (Epub ahead of print)]. This concise review describes current detection methods for CTCs.
Allard WJ, Matera J, Miller MC, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897–6904.
Riethdorf S, Fritsche H, Müller V, et al.: Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch System. Clin Cancer Res 2007, 13:920–928.
Hayes DF, Cristofanilli M, Budd G, et al.: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218–4224.
Danila DC, Heller G, Gignac GA, et al.: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007, 13:7053–7058.
•• Cohen SJ, Punt CJA, Iannotti N, et al.: Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009, 20:1223–1229. This was the first large-scale mCRC patient study examining CTCs. CTC level was shown to correlate with PFS and OS.
Sastre J, Maestro ML, Puente J, et al.: Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008, 19:935–938.
Katsuno H, Zacharakis E, Aziz O, et al.: Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis. Ann Surg Oncol 2008, 15:3083–3091.
•• Cohen SJ, Punt CJA, Iannotti N, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213–3221. This extended analysis of a previous study provides updated follow-up time points. The impact of CTCs on prognosis is examined in several subgroups of patients.
Tol J, Koopman M, Miller MC, et al.: Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2009, 21:1006–1012.
• Garrigós N, Gallego J, Guillén-Ponce C, et al.: Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clin Transl Oncol 2010, 12:142–147. This small study demonstrated the potential of CTCs to predict metastasis in CRC.
Ronzoni M, Manzoni M, Mariucci S, et al.: Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 2010 May 23 (Epub ahead of print).
Findeisen P, Matthias R, Matthias N, et al.: Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol 2008, 33:1001–1010.
Yie SM, Lou B, Ye S, et al.: Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol 2008, 15:3073–3082.
Wong CSC, Cheung MT, Ma BBY, et al.: Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. Int J Surg Pathol 2008, 16:119–126.
Wong SCC, Chan CML, Ma BBY, et al.: Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin Cancer Res 2009, 15:1005–1012.
Schmidt T, Koch M, Antolovic D, et al.: Influence of two different resection techniques (conventional liver resection versus anterior approach) of liver metastases from colorectal cancer on hematogenous tumor cell dissemination—prospective randomized multicenter trial. BMC Surg 2008, 8:6.
Koyanagi K, Bilchik AJ, Saha S, et al.: Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res 2008, 14:7391–7396.
Gervasoni A, Monasterio Muñoz RM, Wengler GS, et al.: Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett 2008, 263:267–279.
Shen C, Hu L, Xia L, et al.: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol 2008, 38:770–776.
Königsberg R, Gneist M, Jahn-Kuch D, et al.: Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. Cancer Lett 2010, 293:117–123.
Chen YF, Wang JY, Wu CH, et al.: Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005, 229:115–122.
• Yen LC, Yeh YS, Chen CW, et al.: Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009, 15:4508–4513. This study demonstrated the clinical feasibility of a novel membrane array for detecting CTCs and the importance of KRAS in CTCs for predicting cetuximab response.
Yang MJ, Chiu HH, Wang HW, et al.: Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 2010, 17:624–633.
• Antolovic D, Galindo L, Carstens A, et al.: Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol 2010, 10:35. This study demonstrated the significant impact of CTC identification method on CTC enumeration.
Uen YH, Lu CY, Tsai HL, et al.: Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I–III colorectal cancer after curative resection. Ann Surg Oncol 2008, 15:2120–2128.
• Papavasiliou P, Fisher T, Kuhn J, et al.: Circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer. Proc (Bayl Univ Med Cent) 2010, 23:11–14. This study found that RFA significantly increases the level of intraoperative CTCs.
Tralhão JG, Hoti E, Serôdio M, et al.: Perioperative tumor cell dissemination in patients with primary or metastatic colorectal cancer. Eur J Surg Oncol (EJSO) 2010, 36:125–129.
Pang R, Law WL, Chu ACY: A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603–617.